Interesting ImagesLow ADC in CNS LymphomaPyatigorskaya, Nadya MD, PhD∗,†; Galanaud, Damien MD, PhD∗,†; Dormont, Didier MD∗,†; Soussain, Carole MD‡; Kas, Aurelie MD, PhD§,∥Author Information From the ∗Assistance Publique Hôpitaux de Paris, Neuroradiology Department, Pitié-Salpêtrière-Charles Foix Hospital, Paris †Sorbonne Université, ICM, Univ Paris 06, UMR S 1127, CNRS UMR 7225, F-75013, Paris ‡Département d'Oncologie Médicale–Hématologie, CLCC Hôpital René Huguenin–Institut Curie, Saint-Cloud §Assistance Publique Hôpitaux de Paris, Nuclear Medicine Department, Pitié Salpêtrière-Charles Foix Hospital, AP-HP ∥Sorbonne University, Laboratoire d'Imagerie Biomédicale, INSERM U1146, Paris, France. Received for publication November 27, 2019; revision accepted March 12, 2020. Conflicts of interest and sources of funding: none declared. Correspondence to: Pyatigorskaya Nadya, MD, PhD, Service de Neuroradiologie, Hôpital Pitié-Salpêtrière, 47-83 Boulevard de l'Hôpital, 75651 Paris Cedex 13, France. E-mail: email@example.com. Clinical Nuclear Medicine: July 2020 - Volume 45 - Issue 7 - p 545-546 doi: 10.1097/RLU.0000000000003067 Buy Metrics Abstract Patients with primary central nervous system lymphomas (PCNSLs) present with nonspecific clinical symptoms, which makes correct imaging evaluation essential for diagnostic and therapeutic management. In this work, we examined an 81-year-old man with recently discovered PCNSL using 18F-FDG PET/MRI, and we were able to differentiate between 2 lesions—PCNSL lymphoma extension and a recent ischemia. Our work shows that ischemia should be considered as a differential diagnosis for lymphoma progression. Although 18F-FDG PET or MRI alone cannot always give unambiguous solution, PET/MRI can greatly improve the diagnosis accuracy and help decide on the appropriate patient management. Copyright © 2020 Wolters Kluwer Health, Inc. All rights reserved.